PDF(Pubmed)
Abstract：
UNASSIGNED: To evaluate and compare the effectiveness of Endoflas and Zinc Oxide Eugenol (ZOE) as root canal filling materials (RCFMs) for the pulpectomy of deciduous teeth by analyzing multiple clinical and radiographic success and failure follow-ups in previously published studies.
UNASSIGNED: All clinical studies that investigated the pulpectomy of the deciduous teeth of children aged 3-9 years.
UNASSIGNED: The databases used for source identification included MEDLINE (via PubMed), Scopus, Web of Science, and the Cochrane Library. No limitations were imposed on the publication year or language. The selection of studies and extraction of relevant study characteristics were conducted from December 26, 2021, to September 7, 2023. Additionally, the risk of bias (RoB) in the included studies was evaluated by using a RoB instrument (RoB 2). Eligible studies were then combined, and a random-effects model was applied by using the maximum likelihood estimations of log risk ratios and their corresponding 95% confidence intervals.
UNASSIGNED: Of the 3913 records found in the abovementioned databases, nine were eligible for systematic review and eight were eligible for meta-analysis. The studies included 628 pulpectomies of deciduous molar teeth in children. The overall results showed that compared with Endoflas, ZOE was associated with a higher risk ratio for clinical evaluation (LOG[RR] = 0.06, CI 0.03-0.09, p-value 0.001) and radiographic evaluation (LOG[RR] = 0.68, CI 0.35-1.00, p-value 0.001). This association was highly significant at 6- and 9-month follow-ups.
UNASSIGNED: Compared with ZOE, Endoflas was associated with a lower risk of the clinical and radiographic failure of deciduous teeth pulpectomy and a 6%-6.8% higher risk ratio, especially at 6- and 9-month follow-ups.
UNASSIGNED: This study suggests the superiority of Endoflas over ZOE as an RCFM for deciduous teeth.
UNASSIGNED: All clinical studies that investigated the pulpectomy of the deciduous teeth of children aged 3-9 years.
UNASSIGNED: The databases used for source identification included MEDLINE (via PubMed), Scopus, Web of Science, and the Cochrane Library. No limitations were imposed on the publication year or language. The selection of studies and extraction of relevant study characteristics were conducted from December 26, 2021, to September 7, 2023. Additionally, the risk of bias (RoB) in the included studies was evaluated by using a RoB instrument (RoB 2). Eligible studies were then combined, and a random-effects model was applied by using the maximum likelihood estimations of log risk ratios and their corresponding 95% confidence intervals.
UNASSIGNED: Of the 3913 records found in the abovementioned databases, nine were eligible for systematic review and eight were eligible for meta-analysis. The studies included 628 pulpectomies of deciduous molar teeth in children. The overall results showed that compared with Endoflas, ZOE was associated with a higher risk ratio for clinical evaluation (LOG[RR] = 0.06, CI 0.03-0.09, p-value 0.001) and radiographic evaluation (LOG[RR] = 0.68, CI 0.35-1.00, p-value 0.001). This association was highly significant at 6- and 9-month follow-ups.
UNASSIGNED: Compared with ZOE, Endoflas was associated with a lower risk of the clinical and radiographic failure of deciduous teeth pulpectomy and a 6%-6.8% higher risk ratio, especially at 6- and 9-month follow-ups.
UNASSIGNED: This study suggests the superiority of Endoflas over ZOE as an RCFM for deciduous teeth.
摘要：
■通过分析先前发表的多项临床和影像学成功和失败的随访，评估和比较Endoflas和氧化锌丁香酚（ZOE）作为根管填充材料（RCFMs）用于乳牙牙髓切除术的有效性。
■调查3-9岁儿童乳牙牙髓切除术的所有临床研究。
■用于源识别的数据库包括MEDLINE（通过PubMed），Scopus,WebofScience,还有Cochrane图书馆.对出版年份或语言没有任何限制。从2021年12月26日至2023年9月7日进行了研究的选择和相关研究特征的提取。此外,纳入研究的偏倚风险(RoB)采用RoB仪器(RoB2)进行评估.然后合并符合条件的研究，通过使用对数风险比的最大似然估计及其相应的95％置信区间，应用了随机效应模型。
■在上述数据库中找到的3913条记录中，9人符合系统评价的条件,8人符合荟萃分析的条件.研究包括628例儿童乳磨牙的牙髓切除术。总体结果表明，与Endoflas相比，对于临床评估（LOG[RR]=0.06，CI0.03-0.09，p值0.001）和影像学评估（LOG[RR]=0.68，CI0.35-1.00，p值0.001），ZOE与较高的风险比相关。这种关联在6个月和9个月的随访中非常显著。
■与ZOE相比，Endoflas与乳牙牙髓切除术的临床和影像学失败的风险较低相关，风险比6％-6.8％。尤其是在6个月和9个月的随访中。
■这项研究表明，Endoflas优于ZOE作为乳牙的RCFM。
■调查3-9岁儿童乳牙牙髓切除术的所有临床研究。
■用于源识别的数据库包括MEDLINE（通过PubMed），Scopus,WebofScience,还有Cochrane图书馆.对出版年份或语言没有任何限制。从2021年12月26日至2023年9月7日进行了研究的选择和相关研究特征的提取。此外,纳入研究的偏倚风险(RoB)采用RoB仪器(RoB2)进行评估.然后合并符合条件的研究，通过使用对数风险比的最大似然估计及其相应的95％置信区间，应用了随机效应模型。
■在上述数据库中找到的3913条记录中，9人符合系统评价的条件,8人符合荟萃分析的条件.研究包括628例儿童乳磨牙的牙髓切除术。总体结果表明，与Endoflas相比，对于临床评估（LOG[RR]=0.06，CI0.03-0.09，p值0.001）和影像学评估（LOG[RR]=0.68，CI0.35-1.00，p值0.001），ZOE与较高的风险比相关。这种关联在6个月和9个月的随访中非常显著。
■与ZOE相比，Endoflas与乳牙牙髓切除术的临床和影像学失败的风险较低相关，风险比6％-6.8％。尤其是在6个月和9个月的随访中。
■这项研究表明，Endoflas优于ZOE作为乳牙的RCFM。
